Upload
anastasiafynn
View
219
Download
0
Embed Size (px)
Citation preview
7/27/2019 2010 Childhood Leukaemia
1/64
A. Osei-Akoto
DCH,SMS-KNUST
7/27/2019 2010 Childhood Leukaemia
2/64
know what leukaemia is
Causes/risk factors/epidemiology
Diagnosis- clinical features/laboratory Prognostic factors
Treatment
7/27/2019 2010 Childhood Leukaemia
3/64
1. General considerations2. Epidemiology and risk factors
3. Clinical presentation
4. Laboratory diagnosis5. Prognostic factors
6. Principles of therapy
7/27/2019 2010 Childhood Leukaemia
4/64
Classified by morphology into LYMPHOCYTIC- cells of lymphoid lineage
NONLYMPHOCYTIC- cells of granulocyte,
monocyte, erythrocyte, or platelet lineage
7/27/2019 2010 Childhood Leukaemia
5/64
97% of all childhood leukaemias Rapidly fatal within weeks to a few months of
diagnosis if untreated; often curable withtreatment
Malignant cells are referred to as BLASTS
7/27/2019 2010 Childhood Leukaemia
6/64
ALL- Acute lymphocytic (lymphoblastic)leukaemia- large numbers of lymphoblasts inBM.
Most common paediatric neoplasm in theworld
80% of all childhood acute leukaemia
7/27/2019 2010 Childhood Leukaemia
7/64
ACUTE NONLYMPHOCYTIC LEUKAEMIA(ANLL)accounts for 20% of acute leukaemiain children
7/27/2019 2010 Childhood Leukaemia
8/64
3% of childhood leukaemias Patients survive for many months to years
even without treatment
Evolve into acute that is not curable Are of non-lymphocytic lineage
Cells are more mature and functional
7/27/2019 2010 Childhood Leukaemia
9/64
Syndromes associated with chromosomalabnormalities- number/stability
Immunodeficiency states Identical twins- 70% risk (if one develops it in
1styr of life); Twins-risk is 2x that in general population if
one develops it between age 5-7yrs Intense treatment for solid tumors eg
Hodgkins, Wilms
7/27/2019 2010 Childhood Leukaemia
10/64
Congenital marrow failure states-Schwachman-Diamond syndrome, Diamond-Blackfan syndrome
Other environmental factors
7/27/2019 2010 Childhood Leukaemia
11/64
Similar clinical features for all the leukaemiasbcos of disruption of Bone marrow function.
Differ in specific clinical and lab features
Marked variation in response to therapy andin prognosis
7/27/2019 2010 Childhood Leukaemia
12/64
BONE MARROW FAILURE- Leukaemic cells in place of normal
haemopoietic elements results in decreasedproduction of rbcs, wbcs, platelets----Aplastic anaemia
7/27/2019 2010 Childhood Leukaemia
13/64
Anaemia- develops slowly1. pallor
2. Irritability
3. Decreased activity- easy fatiguability
7/27/2019 2010 Childhood Leukaemia
14/64
Bleeding tendencies-a. usually due to thrombocytopenia
i. Petechiae and ecchymosis in the skin
ii. Mucosal bleeding, such as epistaxis ormaelena
b. Associated DIC may lead to severe life-threatening bleed- eg in CNS
7/27/2019 2010 Childhood Leukaemia
15/64
Infection due to lack of adequate neutrophils- Fever is the usual symptom/sign
- Localised signs may be absent
- Infection quickly spreads-bacteremia andsepsis
7/27/2019 2010 Childhood Leukaemia
16/64
RES infiltration1. lymphadenopathy- common and may be
massive
2. Hepatosplenomegaly-massive or minimal
7/27/2019 2010 Childhood Leukaemia
17/64
Bone and/or joint pain-expansion of marrow cavity or destruction ofcortical bone by cells
7/27/2019 2010 Childhood Leukaemia
18/64
Involvement of sanctuary sites esp inrecurrence of disease
- CNSdiffuse meningeal irritation
- Testis- unilateral or bilateral enlargement outof proportion to childs sexual development.
7/27/2019 2010 Childhood Leukaemia
19/64
Peripheral blood:normal CBC does notrule out leukaemia
1. Normochromic, normocytic anemia withlow retic count
2. Thrombocytopenia is common3. Neutropenia: low (20,000
in 1/34.Blast cells is common
7/27/2019 2010 Childhood Leukaemia
20/64
BM aspiration- confirmation of diagnosisGold standard for diagnosis- presence of>25% blast cells
7/27/2019 2010 Childhood Leukaemia
21/64
COUNSELLING OF PATIENT and/orPARENTS (FAMILY) IS KEY BEFORESTARTING THERAPY
7/27/2019 2010 Childhood Leukaemia
22/64
SUPPORTIVE CARE1. Transfusional support- often necessary
a. pRbc used for correcting anaemia
b. Platelet concentrates for thrombocytopeniac. Granulocytes rarely needed
7/27/2019 2010 Childhood Leukaemia
23/64
Treatment of infections- very essentialIf fever is present take appropriate Cultures and
start iv broad-spectrum antibiotics Metabolic support- essential to prevent
Tumor Lysis Syndrome:Hyperuricemia, hyperkalaemia,hyperphosphatemia
NEUTROPENIC FEVERH/w
7/27/2019 2010 Childhood Leukaemia
24/64
Treatment of hyperviscosity- EBT andleukopheresis lowers high wbc counts
Treatment of compressive symptoms:
large collection of cells in anteriorMediastinum may produce compressivesymptoms- superior vena cava syndromeetc.
Treatment is by chemotherapy andradiotherapy
7/27/2019 2010 Childhood Leukaemia
25/64
Remission induction- 4 weeks
Objective: successful cytoreduction
Evidence: normal haematopoiesis,
7/27/2019 2010 Childhood Leukaemia
26/64
Consolidation : 14-28weeks1. Kill additional leukaemic cells
2. Prevent relapse within CNS- with therapydirected at the CNS
7/27/2019 2010 Childhood Leukaemia
27/64
Maintenance- longest phase- 2-3yrs1. Continuation of remission
2. Additional cytoreduction for cure
7/27/2019 2010 Childhood Leukaemia
28/64
Discontinuation of therapyPatients who remain in remission throughout
maintenance phase
7/27/2019 2010 Childhood Leukaemia
29/64
Read on the various agents-- action
- side effects
7/27/2019 2010 Childhood Leukaemia
30/64
ALL is a malignant disease; immaturelymphoid cells accumulate in the bonemarrow and replace normal haemopoieticelements.
The malignant cells are released intoperipheral blood, and may spread toinfiltrate all organ systems.
The normal lymphoblast conc. in bonemarrow is 5%.
25% occupancy of BM by lymphoblastconfirms diagnosis of Leukaemia
7/27/2019 2010 Childhood Leukaemia
31/64
Most common childhood cancer; accountsfor 33% of paediatric malignancies
ALL reps about 75% of childhood leukaemias;AML about 20%; 5% CML hardly seen in
children
7/27/2019 2010 Childhood Leukaemia
32/64
ALL is most common type of childhoodleukaemia
More common in whites than blacks
Boys > girls
Peak incidence in 2-6 year old age group
7/27/2019 2010 Childhood Leukaemia
33/64
ALL : 6 (2009), 3 (2010)
BURKITTS : 57 (2009), 72 (2010)
WILMS : 12 (2010) NEUROBLASTOMA: 4 (2010)
7/27/2019 2010 Childhood Leukaemia
34/64
CAUSE IS UNKNOWN The immature lymphoid cells of ALL come
from lymphoid precursor cells in the BMwhich give rise to mature B and T
lymphocytes.
The malignant cells come from clonalproliferation from a single stem or progenitorcell
7/27/2019 2010 Childhood Leukaemia
35/64
Oncogenes/proto-oncogenes : activationof these is thought to trigger eventsleading to leukaemogenesis
1. Chromosome translocation andrearrangements
2. Point mutations
3. Inactivation
4. amplification
7/27/2019 2010 Childhood Leukaemia
36/64
Hereditary- increased incidence in1. Down syndrome- 20-30 fold risk
2. Blooms syndrome
3. Fanconi syndrome/anemia
4. Wiskott-Aldrich syndrome
5. Klinefelter syndrome
6. Ataxia-telangiectasia
7/27/2019 2010 Childhood Leukaemia
37/64
ChemicalsChronic exposure to benzene, akylatingagents eg chlorambucil etc.
Radiation especially to the marrow
Survivors in Japan after atomic bomb,Children of mothers who receive xray during
pregnancy; of fathers who work in nuclearplants;
patients given extended field irradiation
7/27/2019 2010 Childhood Leukaemia
38/64
Predisposing haematological diseases-Hodgkins, multiple myeloma, CML,myeloproliferative diseases
Viruses- eg EBV
7/27/2019 2010 Childhood Leukaemia
39/64
Morphology FAB1. L1(complete) lymphoblast: small with
scanty cytoplasm, inconspicuous nucleoli.Most common type
1. L2 lymphoblasts: larger with abundantcytoplasm, one or more nucleoli. Lesscommon
2. L3- large, deeply basophilic and
vacuolated cytoplasm and prominentnucleoli.
7/27/2019 2010 Childhood Leukaemia
40/64
Immunohistochemistry classification1. Non-T, non-B-cell ALL 84% of cells
a. CALLA-negative early pre-B-cell ALL
b. CALLA-positive ALL
2. B-cell ALL 1%
3. T-cell ALL 15%
7/27/2019 2010 Childhood Leukaemia
41/64
Hepatosplenomegaly 70% Fever 40-60%
Lymphadenopathy 25-50%
Bleeding 25-50%
Bone/joint pain 25-40%
Fatigue 30%
Anorexia 20-35%
7/27/2019 2010 Childhood Leukaemia
42/64
Leukocyte count (mm3)1. < 10,000 45-55%
2. 10,000-50,000 30-35%
3. >50,000 20% Hb (gm/dl)
1. 10 25%
7/27/2019 2010 Childhood Leukaemia
43/64
Platelet count (mm3)1. 100,000 25%
7/27/2019 2010 Childhood Leukaemia
44/64
Factor Favorable unfavorable
WBC 10,000
Age 2-10 yrs 110 yrs
Immunotype CALLA+ CALLA-
Morphology L1 L2, L3
Chromosomes Normal Translocations:
DNA content N/hyperdiploid Hypodiploid,haploid
Bulky disease Absent present
Sex Female male
7/27/2019 2010 Childhood Leukaemia
45/64
A febrile illness (long duration) associatedwith adenopathy
Any disease assoc. with BM failure eg aplasticanaemia
Infectious mononucleosis Infiltration of BM- tumors: neuroblastoma,
rhabdomyosarcoma, Ewing sarcoma,retinoblastoma
7/27/2019 2010 Childhood Leukaemia
46/64
Remission induction: 4-6 weeksSuccessful in 95-98% of children
At least 3 drugs are given- prednisolone,vincristine (oncovin), Methotrexate,Adriamycin /Asparaginase
7/27/2019 2010 Childhood Leukaemia
47/64
Consolidation 14-28 weekscontinuoussystemic therapy
IT methotrexate cranial irradiation is givenfor CNS prophylaxis
7/27/2019 2010 Childhood Leukaemia
48/64
Maintenancetherapy : 2-3yrsDaily oral 6-mercaptopurine(6MP), weekly oral
methotrexate + periodic reinducton pulsesof prednisolone and vincristine
7/27/2019 2010 Childhood Leukaemia
49/64
Continuous complete remission mostcommon outcome
Relapses still occur in 30-40% of patients.Can occur in the
1. Bone marrow- the most common site forrelapse
2. CNS3. Testes- becoming the most common site
of extramedullary relapse
7/27/2019 2010 Childhood Leukaemia
50/64
ALL treatment use lower doses ofchemotherapy over a longer period of time(usually 2 to 3 years)
7/27/2019 2010 Childhood Leukaemia
51/64
vincristine (Oncovin)
daunorubicin, also known as daunomycin(Cerubidine)
doxorubicin (Adriamycin) cytarabine, also known as cytosine
arabinoside or ara-C (Cytosar)
L-asparaginase (Elspar), PEG-L-asparaginase (pegaspargase, Oncaspar)
6-mercaptopurine (Purinethol
7/27/2019 2010 Childhood Leukaemia
52/64
6-thioguanine methotrexate
cyclophosphamide (Cytoxan)
prednisone (numerous brand names)
dexamethasone (Decadron, other
7/27/2019 2010 Childhood Leukaemia
53/64
vincristine (Oncovin) doxorubicin (Adriamycin)
methotrexate
cyclophosphamide (Cytoxan)
prednisone
Dexamethasone
Allopurinol
7/27/2019 2010 Childhood Leukaemia
54/64
Refer to Child Health Treatment Guidelines Regimen induction for patients age
7/27/2019 2010 Childhood Leukaemia
55/64
Remission Rapid early responders
Late early responders
Relapse
Minimal Residual disease
Cure
Read
7/27/2019 2010 Childhood Leukaemia
56/64
Chemotherapy drugs work by attackingcells that are dividing quickly (cancer cells)
cells in the bone marrow, the mucosa of
the mouth and intestines, and the hairfollicles, also divide quickly and are alsoaffected
The side effects depend on type, dose of
drugs, and the length of time they aretaken
7/27/2019 2010 Childhood Leukaemia
57/64
hair loss
mouth sores
loss of appetite
diarrhea nausea and vomiting
increased risk of infections
Bleeding tendencies Fatigue
TLS- tumour lysis syndrome
7/27/2019 2010 Childhood Leukaemia
58/64
Learning disabilities especially in youngchildren
Transient somnolence syndrome
Fatal leucoencephalopathy
Brain tumours
7/27/2019 2010 Childhood Leukaemia
59/64
Bone marrow or peripheral blood stem celltransplant is the answer
Blood-forming stem cells used for atransplant are obtained either from the blood
(for a peripheral blood stem cell transplant,or PBSCT) or from the bone marrow (for abone marrow transplant, or BMT)
7/27/2019 2010 Childhood Leukaemia
60/64
Allogeneic stem cell transplant:
the blood-forming stem cells are generallydonated from another person
The donor's tissue type (also known as theHLA type) should be identical to thepatient's tissue type
Usually the donor is a brother or sister.Commonest method employed.
7/27/2019 2010 Childhood Leukaemia
61/64
Autologous stem cell transplant:
the patient's own stem cells are removedfrom his or her bone marrow (bonemarrow stem cells) or bloodstream
(peripheral blood stem cells, PBSCs).
Cells are frozenand stored during
treatment; purging is done and cells arethen re-infused into the child's blood aftertreatment.
7/27/2019 2010 Childhood Leukaemia
62/64
ANLL AML
7/27/2019 2010 Childhood Leukaemia
63/64
Write short notes on Acute lymphocyticleukaemia (ALL) under the following:
a. Epidemiology and risk factors
b. Clinical presentation
c. Laboratory diagnosis
d. Prognostic factors
e. Principles of therapy
7/27/2019 2010 Childhood Leukaemia
64/64
Nelson textbook of pediatrics- 18thedition NMS pediatrics 3rdedition Pediatric secrets 2ndedition Essential haematology 3rdedition-
Hoffbrand and Pettit Lecture notes on haematology-Huges-Jones, Wickramasinghe
Manual of Pediatric Hematology and
oncology -3rdedition by Lanzkowsky